^(99)Tc^(m)-MIBI SPECT/CT同机融合显像在骨肿瘤中的应用价值  

The Application Value of ^(99)Tc^(m)-MIBI SPECT/CTFusion Imaging in Bone Tumors

作　　者：李铜娜 郭林[1] 金刚[1] LI Tongna;GUO Lin;JIN Gang(Department of Nuclear Medicine,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院核医学科,黑龙江哈尔滨150086

出　　处：《标记免疫分析与临床》2022年第6期1067-1070,共4页Labeled Immunoassays and Clinical Medicine

基　　金：哈尔滨医科大学附属第二医院横向合作课题(99Tcm-MIBI SPECT/CT肿瘤系列融合显像联合肿瘤标志物的临床应用研究)。

摘　　要：近年来,随着SPECT/CT同机融合显像技术的不断发展和应用,亲肿瘤显像剂^(99)Tc^(m)-MIBI在骨肿瘤诊疗方面也随之展现出越来越大的应用价值。本文介绍了显像剂^(99)Tc^(m)-MIBI的显像机制、SPECT/CT同机融合显像技术的特点以及^(99)Tc^(m)-MIBI SPECT/CT同机融合显像在原发性、转移性骨肿瘤诊治中的临床应用价值。In recent studies,with the fast development of SPECT/CT fusion imaging technology,^(99)Tc^(m)-MIBI,as a tumor-friendly imaging agent,has been playing a more and more important role in the clinical application of bone tumors.This paper reviewed the imaging mechanism of ^(99)Tc^(m)-MIBI and the clinical advantages of SPECT/CT co-fusion,also explored the clinical value of ^(99)Tc^(m)-MIBI SPECT/CT co-fusion imaging in primary bone tumors and metastatic bone tumors.

关 键 词：^(99)Tc^(m)-MIBI SPECT/CT 骨肿瘤 应用价值 

分 类 号：R817.5[医药卫生—影像医学与核医学]